ADVFN Logo ADVFN
시장 데이터
뉴스
도구
시장
팔로우

Hot Features

피드 팔로우

Follow Feed 커뮤니티에서 거래자 및 투자자와 연결하세요.

실시간 옵션 플로우

포괄적인 옵션 데이터를 탐색하고 옵션 흐름으로 고급 필터를 사용하세요.

모니터

터미널 모니터로 주식 및 자산 관심 목록을 구성하고 모니터링하세요.
로그인 Premium Icon프리미엄 Help Menu
S&P 500
5,099.96
1.02%
US Tech 100
17,244.80
1.57%
다우존스 지수
38,239.66
0.40%
Bitcoin
62,032.07
-1.54%
Registration Strip Icon for monitor 브라질 증권 거래소, NASDAQ, NYSE, AMEX, LSE 등 주요 거래소에서의 다양한 실시간 주식 시세를 모니터링합니다.
등록
  1. 홈
  2. 인베스팅
  3. 주식
  4. 미국
  5. NASDAQ
  6. Immunic Inc (IMUX)

  7. Immunic Inc (IMUX) 뉴스

IMUX Immunic Inc

1.22
-0.04 (-3.17%)
27 4월(4) 2024 - 마감
15분 지연
기업명 주식 심볼 시장 주식 타입
Immunic Inc IMUX 나스닥 보통주
  가격 변동 가격 변동 % 주식 가격 최근 거래 시간
Upgrade Icon
-0.04 -3.17% 1.22 13:00:11
개장가 저가 고가 종가 전일 종가
1.26 1.19 1.28 1.22 1.26
시세 정보 더보기 »

최근 뉴스

일자 시간 출처 제목
04/04/202419:30PRNUSImmunic to Host MS R&D Day and Participate in Investor..
20/03/202419:30PRNUSImmunic Receives Notice of Allowance for..
09/03/202406:05EDGAR2Form 8-K - Current report
07/03/202420:30PRNUSImmunic to Participate in Investor and Scientific..
07/03/202411:52EDGAR2Form 4 - Statement of changes in beneficial ownership of..
07/03/202411:51EDGAR2Form 4 - Statement of changes in beneficial ownership of..
07/03/202411:51EDGAR2Form 4 - Statement of changes in beneficial ownership of..
07/03/202411:50EDGAR2Form 4 - Statement of changes in beneficial ownership of..
07/03/202411:50EDGAR2Form 4 - Statement of changes in beneficial ownership of..
07/03/202411:50EDGAR2Form 4 - Statement of changes in beneficial ownership of..
29/02/202420:30PRNUSImmunic Presents Data From Phase 2 CALLIPER and CALVID-1..
22/02/202420:38EDGAR2Form 10-K - Annual report [Section 13 and 15(d), not S-K..
22/02/202420:35EDGAR2Form 8-K - Current report
22/02/202420:30PRNUSImmunic, Inc. Reports Year End 2023 Financial Results and..
15/02/202420:30PRNUSImmunic, Inc. to Announce Financial Results for the Year..
15/02/202406:05EDGAR2Form SC 13G/A - Statement of acquisition of beneficial..
14/02/202422:47EDGAR2Form SC 13G/A - Statement of acquisition of beneficial..
14/02/202421:55EDGAR2Form SC 13G/A - Statement of acquisition of beneficial..
14/02/202406:36EDGAR2Form S-3 - Registration statement under Securities Act of..
05/02/202422:30EDGAR2Form DEF 14A - Other definitive proxy statements
01/02/202420:30PRNUSImmunic to Participate in Investor and Scientific..
25/01/202407:05EDGAR2Form PRE 14A - Other preliminary proxy statements
20/01/202406:07EDGAR2Form 4 - Statement of changes in beneficial ownership of..
20/01/202406:07EDGAR2Form 4 - Statement of changes in beneficial ownership of..
20/01/202406:06EDGAR2Form 4 - Statement of changes in beneficial ownership of..
20/01/202406:06EDGAR2Form 4 - Statement of changes in beneficial ownership of..
20/01/202406:05EDGAR2Form D - Notice of Exempt Offering of Securities
17/01/202406:12EDGAR2Form SC 13G - Statement of acquisition of beneficial..
10/01/202423:00EDGAR2Form SC 13G - Statement of acquisition of beneficial..
05/01/202420:41EDGAR2Form 8-K - Current report
05/01/202420:35PRNUSImmunic Highlights 2023 Accomplishments and Upcoming..
05/01/202420:30PRNUSImmunic, Inc. Announces Private Placement of up to $240..
21/12/202322:30EDGAR2Form 8-K - Current report
23/11/202306:20EDGAR2Form S-3 - Registration statement under Securities Act of..
21/11/202320:30PRNUSImmunic Receives Notice of Allowance for United States..
14/11/202320:38EDGAR2Form 8-K - Current report
14/11/202320:30PRNUSImmunic, Inc. Reports Third Quarter 2023 Financial Results..
07/11/202320:30PRNUSImmunic to Announce Financial Results for the Third Quarter..
02/11/202319:30PRNUSImmunic Receives Notice of Allowance for United States..
26/10/202319:30PRNUSImmunic to Participate in Scientific and Industry..
19/10/202305:05EDGAR2Form 8-K - Current report
16/10/202319:30PRNUSImmunic Presents Data From Phase 2 CALDOSE-1 Trial of..
15/10/202319:30PRNUSImmunic Presents Data From Phase 1b Clinical Trial of..
11/10/202319:30PRNUSImmunic Presents Data From Phase 2 EMPhASIS Trial of..
10/10/202321:48EDGAR2Form 8-K - Current report
10/10/202305:01PRNUSImmunic Reports Positive Interim Data from Phase 2 CALLIPER..
04/10/202319:30PRNUSImmunic to Participate in Scientific Conferences in October
06/09/202319:30PRNUSImmunic to Participate in Industry and Investor Conferences..
21/08/202319:30EDGAR2Form S-8 - Securities to be offered to employees in employee..
17/08/202319:30PRNUSImmunic Completes Enrollment of Its Phase 2 CALLIPER Trial..

최근 히스토리

NASDAQ
IMUX
Immunic
Delayed Upgrade Clock
ADVFN Logo

대한변국
회사 소개
사업
Popular
앱 받기

도움 및 지원받기: kr-support@advfn.com

ADVFN 서비스 이용은 ADVFN의 이용약관에 동의하는 것입니다 이용약관

© 2024 ADVFN PLC - 모든 권리 보유